• Je něco špatně v tomto záznamu ?

Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity

ÍA. Fernandes, D. Braga Resende, TC. Ramalho, K. Kuca, EFF. da Cunha

. 2020 ; 25 (7) : . [pub] 20200409

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012712

Grantová podpora
CAPES CNPq
Excellence project UHK CEP - Centrální evidence projektů

FLT3 and dual Aurora B/FLT3 inhibitors have shown relevance in the search for promising new anticancer compounds, mainly for acute myeloid leukemia (AML). This study was designed to investigate the interactions between human FLT3 in the kinase domain with several indolin-2-one derivatives, structurally similar to Sunitinib. Molegro Virtual Docker (MVD) software was utilized in docking analyses. The predicted model of the training group, considering nineteen amino acid residues, performed in Chemoface, achieved an R2 of 0.82, suggesting that the binding conformations of the ligands with FLT3 are reasonable, and the data can be used to predict the interaction energy of other FLT3 inhibitors with similar molecular patterns. The MolDock Score for energy for compound 1 showed more stable interaction energy (-233.25 kcal mol-1) than the other inhibitors studied, while Sunitinib presented as one of the least stable (-160.94 kcal mol-1). Compounds IAF70, IAF72, IAF75, IAF80, IAF84, and IAF88 can be highlighted as promising derivatives for synthesis and biological evaluation against FLT3. Furthermore, IAF79 can be considered to be a promising dual Aurora B/FLT3 inhibitor, and its molecular pattern can be exploited synthetically to search for new indolin-2-one derivatives that may become drugs used in the treatment of cancers, including AML.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012712
003      
CZ-PrNML
005      
20210507103633.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules25071726 $2 doi
035    __
$a (PubMed)32283751
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fernandes, Ítalo Antônio $u Department of Chemistry, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil
245    10
$a Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity / $c ÍA. Fernandes, D. Braga Resende, TC. Ramalho, K. Kuca, EFF. da Cunha
520    9_
$a FLT3 and dual Aurora B/FLT3 inhibitors have shown relevance in the search for promising new anticancer compounds, mainly for acute myeloid leukemia (AML). This study was designed to investigate the interactions between human FLT3 in the kinase domain with several indolin-2-one derivatives, structurally similar to Sunitinib. Molegro Virtual Docker (MVD) software was utilized in docking analyses. The predicted model of the training group, considering nineteen amino acid residues, performed in Chemoface, achieved an R2 of 0.82, suggesting that the binding conformations of the ligands with FLT3 are reasonable, and the data can be used to predict the interaction energy of other FLT3 inhibitors with similar molecular patterns. The MolDock Score for energy for compound 1 showed more stable interaction energy (-233.25 kcal mol-1) than the other inhibitors studied, while Sunitinib presented as one of the least stable (-160.94 kcal mol-1). Compounds IAF70, IAF72, IAF75, IAF80, IAF84, and IAF88 can be highlighted as promising derivatives for synthesis and biological evaluation against FLT3. Furthermore, IAF79 can be considered to be a promising dual Aurora B/FLT3 inhibitor, and its molecular pattern can be exploited synthetically to search for new indolin-2-one derivatives that may become drugs used in the treatment of cancers, including AML.
650    _2
$a algoritmy $7 D000465
650    _2
$a aurora kinasa B $x antagonisté a inhibitory $x chemie $7 D064107
650    _2
$a aktivace enzymů $x účinky léků $7 D004789
650    _2
$a lidé $7 D006801
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a molekulární modely $7 D008958
650    12
$a teoretické modely $7 D008962
650    _2
$a molekulární konformace $7 D008968
650    _2
$a molekulární struktura $7 D015394
650    _2
$a inhibitory proteinkinas $x chemie $x farmakologie $7 D047428
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a tyrosinkinasa 3 podobná fms $x antagonisté a inhibitory $x chemie $7 D051941
655    _2
$a časopisecké články $7 D016428
700    1_
$a Braga Resende, Déborah $u Department of Veterinary Medicine, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil
700    1_
$a Ramalho, Teodorico Castro $u Department of Chemistry, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil $u Faculty of Science, Department of Chemistry, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Kuca, Kamil $u Faculty of Science, Department of Chemistry, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic
700    1_
$a da Cunha, Elaine Fontes Ferreira $u Department of Chemistry, Federal University of Lavras, P.O. Box 3037, Lavras-MG 37200-000, Brazil
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 25, č. 7 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32283751 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103632 $b ABA008
999    __
$a ok $b bmc $g 1650971 $s 1133091
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 25 $c 7 $e 20200409 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
GRA    __
$a CAPES $p CNPq
GRA    __
$a Excellence project $p UHK
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

    Možnosti archivace